Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
NUVOLA TRIAL Open-label Multicentre Study (NUVOLA)

peritoneal tumour load. Nonetheless, BRCAmut women additionally show a higher benefit of platinum-based neoadjuvant chemotherapy (NACT) plus interval debulking surgery compared with BRCAwt women in

  • 0 views
  • 26 Feb, 2022
  • 1 location
Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer

status. Neoadjuvant chemotherapy(NAC) followed interval debulking surgery (IDS) is an alternative therapeutic option for these patients. There is growing interest in the use of HIPEC (hyperthermic

ovarian epithelial carcinoma
ovarian epithelial cancer
cancer of the ovary
intraperitoneal chemotherapy
peritoneal cancer
  • 8 views
  • 27 Feb, 2022
  • 1 location
Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer (ROCOCO)

Te hypothesized that two cycles of neoadjuvant chemotherapy followed by interval debulking surgery would improve survival in advanced epithelial ovarian, fallopian, and primary peritoneal cancer

adenocarcinoma
peritoneal cancer
cytoreductive surgery
neutrophil count
tumor debulking
  • 45 views
  • 20 Feb, 2022
Using Aspirin to Improve Immunological Features of Ovarian Tumors

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in

fallopian tube
measurable disease
interval debulking surgery
neutrophil count
peritoneal carcinoma
  • 0 views
  • 23 Dec, 2021
  • 1 location
Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting

This study aims to evaluate the effects of niraparib in those who have received neoadjuvant chemotherapy and subsequent interval debulking surgery, with or without hyperthermic intraperitoneal

cancer of the ovary
niraparib
intraperitoneal chemotherapy
fallopian tube
cytoreductive surgery
  • 0 views
  • 06 Oct, 2021
  • 1 location
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) (CHIPPI)

(PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC combined with standard care

cancer of the ovary
hysterectomy
adenocarcinoma
intraperitoneal chemotherapy
interval debulking surgery
  • 3 views
  • 07 Feb, 2022
  • 6 locations
Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy (OLIVIA)

surgery. [18F]FB-IL2 PET-CT will be used for the non-invasive assessment of T-cell activation and correlated to immunohistochemistry tumor tissue data from pre-treatment biopsy and interval debulking

cancer of the ovary
interval debulking surgery
tumor debulking
cancer chemotherapy
carboplatin/paclitaxel
  • 2 views
  • 19 Feb, 2022
  • 1 location
Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer

arm clinical trial. Included patients will receive interval debulking surgery after 2-6 cycles neoadjuvant chemotherapy based on the clinical judgment of the gynecologic oncologist. Six cycles of

  • 0 views
  • 18 Aug, 2021
  • 1 location
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)

The purpose of this study is to answer the fundamental question, should the physicians choose Surgery or Chemotherapy (SOC-2) in advanced ovarian cancer?

ovarian epithelial cancer
cancer of the ovary
adenocarcinoma
carcinoma
cancer antigen 125
  • 505 views
  • 22 Oct, 2021
  • 7 locations
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer

This study was designed to assess the safety and efficacy of neoadjuvant therapy with mitomycin C plus cisplatin (MP) in BRCA1-mutated ovarian cancer versus standard regimen (paclitaxel plus carboplatin (TP)).

  • 0 views
  • 18 Feb, 2021
  • 1 location